Gadolinium Toxicity Symptoms: What Patients Report

Gadolinium toxicity symptoms are symptoms reported after gadolinium-based contrast agents (GBCAs) used during MRI scans. Some people use the term Gadolinium Deposition Disease (GDD) when symptoms persist and retention is suspected or documented. Reported symptoms include nerve pain, brain fog, skin changes, bone pain, fatigue, and hair loss.

Symptoms vary from person to person, and this page should not be used to diagnose yourself. It brings together high-level findings from Signs & Symptoms after Gadolinium Administration: A Patient Survey — the 2025 patient survey by Williams and colleagues, published by GadoliniumToxicity.com — along with related research and collective patient observations. The full survey included 316 people; 185 had laboratory-confirmed retention and 131 were never tested. The goal is to help you compare timing and symptom patterns, then bring clearer information to a clinician.

Establishing the Gadolinium Toxicity Connection

Some people notice symptoms soon after a contrast MRI. Others start looking back only after months of unexplained problems, testing, or repeated appointments. Both situations can be disorienting, especially when the timing feels clear to the patient but the connection is dismissed or left unexplored. This section is meant to help organize that question without promising a single explanation or cure. More support options are covered in What Helps.

New symptoms after MRI contrast?

Start with a practical pathway for documenting exposure, tracking symptom timing, requesting records, and preparing for a clinician conversation.

Try the Gadolinium Symptom Checker

Want a structured way to compare your symptoms and MRI contrast history with published post-GBCA patterns? Use the checker for an educational pattern-fit result before discussing next steps with a clinician.

Open Symptom Checker

Key Findings

Survey Participants

316 patients with normal or near-normal kidney function who experienced symptoms after MRI with a GBCA, plus 8 patients with biopsy-confirmed nephrogenic systemic fibrosis (NSF) — a rare scarring disease of the skin and organs seen in people with severe kidney disease. Of the 316, 185 had laboratory-confirmed gadolinium retention and 131 were never tested.

Gadolinium Retention Confirmed

185 patients had laboratory tests confirming gadolinium retention 30 days or longer after their last MRI, with some cases showing retention for up to 22 years. The symptom percentages on this site come from these 185 patients, not from all 316.

Symptom Overlap with NSF

19 of the 28 most frequently reported symptoms in the NSF Group were also ranked among the top symptoms reported by patients with normal kidney function, indicating substantial overlap in clinical presentation.

Nervous System Impact

11 of the 19 most frequently reported symptoms across all patient groups involve the nervous system, consistent with gadolinium's toxic effects on calcium channels.

Unconfounded Cases

75 patients received only one type of GBCA (19 linear & 56 macrocyclic) with confirmed gadolinium retention. The same 14 nervous system symptoms ranked in the top 25 for both linear and macrocyclic agents.

Chronic Effects

43% of patients reported changes in employment status due to health issues, and 41% said altered brain function affects their ability to work as they did prior to MRIs.

Explore Symptoms In-Depth

Common Symptoms

The most frequently reported symptoms from the 185 survey participants with laboratory-confirmed gadolinium retention, including nerve pain, brain fog, burning sensations, and muscle twitching — with frequency data by body system.

See the full symptom list

Symptom Progression

How symptoms develop over time — from acute early-phase reactions within hours or days of MRI contrast to chronic long-term effects lasting months to years.

See the symptom timeline

By Body System

Detailed symptom data organized by body system — nervous, skeletal, skin, endocrine, cardiovascular, digestive, and more — plus the survey methodology and conclusions.

See symptoms by body system

Common Questions

What are the symptoms of gadolinium toxicity?
The most commonly reported gadolinium toxicity symptoms include tingling/prickling sensations (79%), brain fog (72%), burning pain (69%), muscle twitching (69%), fatigue (65%), joint pain (61%), deep bone pain (57%), vision changes (49%), and hair loss (35%). These percentages are the share of the 185 survey participants with laboratory-confirmed gadolinium retention who reported each symptom. The full survey included 316 people; 185 had laboratory-confirmed retention and 131 were never tested. These are self-reported answers to an online questionnaire, not measured rates of illness after MRI contrast.
How long do gadolinium side effects last?
Gadolinium side effects can persist for months to years. In the patient survey, 185 patients had laboratory tests confirming gadolinium retention 30 days or more after their last MRI, with some cases showing retention for up to 22 years. Symptom duration varies widely — some patients report improvement over time, while others experience chronic symptoms.
Can gadolinium cause hair loss?
Yes, hair loss is reported by approximately 35% of patients in published gadolinium toxicity surveys, and up to 50% in early-phase NSF cases. Community reports indicate hair loss can begin within days of MRI contrast exposure. Many patients report improvement over 3-12 months, though recovery timelines vary widely.
What is Gadolinium Deposition Disease (GDD)?
Gadolinium Deposition Disease (GDD) is a condition where gadolinium from MRI contrast agents is retained in body tissues, causing symptoms in patients with normal kidney function. The 19 most frequently reported symptoms in patients with nephrogenic systemic fibrosis (NSF) — a rare scarring disease of the skin and organs seen in people with severe kidney disease — overlap substantially with those reported by patients with normal kidney function, suggesting a gadolinium-related symptom spectrum.
How do I know if I have gadolinium toxicity?
Gadolinium toxicity is suggested by the development of new symptoms after receiving gadolinium-based MRI contrast, particularly if symptoms include nerve pain, burning sensations, brain fog, bone pain, or skin changes. Laboratory testing can confirm gadolinium retention through 24-hour urine tests. A pattern-matching tool like the Symptom Checker can help assess symptom overlap with published data.

Where to Go Next

Sources and Review

Editorial reviewed

Author: Gadolinium.org Editorial Team (Patient-Led Education)

Last reviewed: February 21, 2026

How this page was reviewed: Reviewed against published patient-survey findings and physician-linked educational sources on this page.

Clinician review: No physician has reviewed this page. It was checked by the editorial team against the sources listed below.

This page is for education only and is not a diagnosis or treatment plan.